Lymphoma Clinical Trials & Research

Our mission has always been a singular one: to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments, and many of our innovations and approaches have set the standard for care. We won’t give up until we conquer cancer.

In fact, we’re currently studying new approaches to treating lymphoma, and we come closer to finding exciting solutions every day. One of the most important goals we have is to develop new and improved treatments for people with lymphoma who are not helped by standard treatments.

Our doctors are leading a large number of clinical trials to test new drugs and drug combinations. We’re on the hunt for genetic factors linked to lymphoma development and other strategies for improving treatment. These research studies are based on our growing understanding of how lymphoma is different from other cancers, and the research is increasingly “translational,” meaning that discoveries made in the lab are taken directly to our patients.

In other words, choosing MSK may give you access to new treatment options before they’re widely available elsewhere. We have extensive experience in matching patients with the right clinical trials that will benefit them the most.

We do research in:

  • New chemotherap​y approaches
    Our physicians are investigating the effectiveness of various combinations of chemotherapeutic agents and other drugs for non-Hodgkin lymphoma.
  • Pathway-directed (biologic) therapies
    Our investigators are testing drugs that are designed to interrupt or restrain the molecular processes that tumor cells require to grow and spread.
  • Immune strategies
    We’re testing investigational drugs aimed at encouraging the body’s immune system to identify and react against cancer cells.
  • Tumor-directed therapies (radiolabeled antibodies)
    Our researchers are investigating the effectiveness of antibodies (proteins that specifically target cancer cells and carry radioactive molecules) that can potentially kill cancer cells with radiation while minimizing exposure to the rest of the body.

Untreated (Newly Diagnosed)

A Phase Ib/II Study Combining Chemotherapy and Immunotherapy for the Treatment of Non-Hodgkin Lymphoma
Anas Younes
[Protocol 16-006]

Prior Treatment (Relapsed/Refractory)

A Phase Ib/II Study Combining Chemotherapy and Immunotherapy for the Treatment of Non-Hodgkin Lymphoma
Anas Younes
[Protocol 16-006]

A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]

A Phase III Study of Rituximab with and without Copanlisib in Patients with Recurrent B-Cell Non-Hodgkin Lymphoma
John F. Gerecitano
[Protocol 15-236]

A Phase II Study of Standard Therapies with or without Polatuzumab Vedotin in Patients with Recurrent or Persistent B-Cell Lymphomas
Matthew J. Matasar
[Protocol 15-170]

A Phase I Study of JNJ-64052781 in Patients with Recurrent or Persistent B-Cell Cancers
Anas Younes
[Protocol 15-125]

A Phase IB/IIA Study of Carfilzomib, Romidepsin, and Lenalidomide in Patients with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 14-179]

A Phase IB Study of Immunotherapy with Atezolizumab plus Obinutuzumab in Patients with Recurrent or Persistent Lymphoma
M. Lia Palomba
[Protocol 14-220]

A Phase I Study of MT-3724 for the Treatment of Relapsed B-cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-265]

A Phase II Study of Mocetinostat in Patients with Diffuse Large B-cell Lymphoma or Follicular Lymphoma with Certain Mutations
[Protocol 14-106]

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-023]

A Phase IB Study of MK-3475 (Pembrolizumab) Immunotherapy in Patients with Myelodysplastic Syndromes and Lymphoma
Craig H. Moskowitz
[Protocol 13-220]

Untreated (Newly Diagnosed)

A Phase IB Study of GDC-0199 (ABT-199 or Venetoclax) with R-CHOP or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
[Protocol 14-130]

Prior Treatment (Relapsed/Refractory)

A Phase II Study of RICE Chemotherapy with and without SGN19 in Patients with Recurrent or Persistent Diffuse B-Cell Lymphoma
Craig H. Moskowitz
[Protocol 16-008]

A Phase I Study of ADCT-301 in Patients with Persistent or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Steven M. Horwitz
[Protocol 15-300]

A Phase II Study of Standard Therapies with or without Polatuzumab Vedotin in Patients with Recurrent or Persistent B-Cell Lymphomas
Matthew J. Matasar
[Protocol 15-170]

A Phase I Study of JNJ-64052781 in Patients with Recurrent or Persistent B-Cell Cancers
Anas Younes
[Protocol 15-125]

A Phase I Study of MT-3724 for the Treatment of Relapsed B-cell Non-Hodgkin Lymphoma
Paul A. Hamlin
[Protocol 14-265]

A Phase IB/IIA Study of Carfilzomib, Romidepsin, and Lenalidomide in Patients with Recurrent or Persistent Lymphoma
Steven M. Horwitz
[Protocol 14-179]

A Phase II Study of Mocetinostat in Patients with Diffuse Large B-cell Lymphoma or Follicular Lymphoma with Certain Mutations
[Protocol 14-106]

A Phase IB Study of MK-3475 (Pembrolizumab) Immunotherapy in Patients with Myelodysplastic Syndromes and Lymphoma
Craig H. Moskowitz
[Protocol 13-220]

A Phase I Study of Ibrutinib plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
Craig S. Sauter
[Protocol 14-145]